Parkinson s Well-Being Map TM

Similar documents
Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Appendix 2: Admissions checklists for people with Parkinson s

The Fresco Institute for Parkinson's and Movement Disorders

PARKINSON S MEDICATION

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

Optimizing Clinical Communication in Parkinson s Disease:

Summary of Patient < 3y at Visit 11 (90 months)

An Overview of Parkinson s Medication used in Multiple System Atrophy

An Overview of Parkinson s Medication used in Multiple System Atrophy

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

Thinking about advanced parkinson S

Best Medical Treatments for Parkinson s disease

Medication Management & Strategies When the levodopa honeymoon is over

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Scottish Medicines Consortium

Parkinson s Disease Medications: Professionals Edition

Medications used to treat Parkinson s disease

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Parkinson s Disease Current Treatment Options

Clinical Guideline for the management of inpatients with Parkinson s disease

Sleep and Night-time Problems in Parkinson s

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL

Key Concepts and Issues in Parkinson s Disease in 2016

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

PARKINSON S SYMPTOM TRACKER

Non-Motor Symptoms of Parkinson s Disease

Drugs Affecting the Central Nervous System

Understanding Parkinson s Disease Important information for you and your loved ones

NMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM

Parkinson s disease: diagnosis and current management

Commonly encountered medications and their side effects - what the generalist needs to know

Acute management of in-patient Parkinson s Disease patients

10th Medicine Review Course st July Prakash Kumar

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Parkinson's Disease and how you can make a difference with medication

Parkinson s Disease. Gillian Sare

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Common medicines given to neurology patients on discharge from hospital

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Section 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

DYSKINESIA SYMPTOM TRACKER

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

SPEAKING UP ABOUT OFF PERIODS

New Medicines Committee Briefing July 2011

Evaluation and Management of Parkinson s Disease in the Older Patient

Issues for Patient Discussion

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.

What is Parkinson s Disease?

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Parkinsonism. Parkinsonism. James Parkinson A syndrome. Causes of Parkinsonism

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

DOCTOR DISCUSSION GUIDE

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Dependency and transfer incomes in idiopathic Parkinson s disease

DEEP BRAIN STIMULATION SURGICAL CANDIDACY EVALUATION FORM

Parkinson s Disease. Medications

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Communicating About OFF Episodes With Your Doctor

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

Parkinson s Pharmacology

Aripiprazole Accord 5, 10, 15 and 30 mg film-coated tablets

What s new for diagnosing and treating Parkinson s Disease?

PD: Key Treatment Considerations

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE

Parkinson s Disease Foundation. PD ExpertBriefing: Managing the Motor Symptoms in PD

WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS

(safinamide) tablets

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Final Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?

Facial Problem(s) Questionnaire

Advances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL

PRODUCT MONOGRAPH. Pr PROLOPA. levodopa and benserazide capsules. 50 mg mg, 100 mg - 25 mg, 200 mg - 50mg. Pharmaceutical standard: professed

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

XADAGO (safinamide) oral tablet

Dr Barry Snow. Neurologist Auckland District Health Board

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL. Reviewer s Name, Title & address:

The PD You Don t See: Cognitive and Non-motor Symptoms

Options for Treating Restless Legs Syndrome. A Review of the Research for Adults

Patient/Caregiver Information Brochure For Bipolar I Disorder in Adolescents

YOUR GUIDE TO ARIPIPRAZOLE Patient/Caregiver Information Brochure

Headway Victoria Epilepsy and Parkinson s Centre

Literature Scan: Anti-Parkinson s Agents

Transcription:

Parkinson s Well-Being Map TM Supporting communication of my Parkinson s The Parkinson s Well-Being Map TM has been endorsed by: Developed in partnership with UCB. All rights reserved 0 UCB, Trademarks indicated or are the property of their respective owners CNS-OTH-0868-070 UK/NE08c CNS-OTH-0868-070 UK/NE08c DOP: February 0

Introduction Parkinson s disease is a progressive, chronic neurodegenerative disease. The prevalence in industrialised nations is estimated at in 00 people over the age of 60 and is rarer in people under 50 years of age. It is predominantly characterised by problems with body movements, known as motor symptoms the most recognisable being tremor. However, the non-motor symptoms are missed by neurologists in 59% of consultations and also often undeclared by people with Parkinson s to healthcare professionals resulting in under-diagnosis and under treatment. The Parkinson s Well-Being Map has been developed to support communication of a person s Parkinson s status with their care team. Using the Map you are able to: TM Monitor your condition Review your motor and non-motor symptoms Make the most of your consultation to focus on the questions important to you. de Lau LM, Breteler MM. Epidemiology of Parkinson s disease. Lancet Neurol. 006 Jun;5(6):55-5.. Shulman LM et al. Parkinsonism Relat Disord 00;8():9 97. Clarke CE et al. Br J Clin Pract 995;9(6):88 9 CNS-OTH-0868-070 UK/NE08c DOP: February 0

How to complete the Parkinson s Well-Being Map TM Mood Parkinson s Well-Being Map TM Often Always well-being Never Occasionally Sometimes I have difficulty falling asleep at night I have difficulty staying asleep I have difficulty getting back to sleep once awake I have morning tiredness I have fatigue during the day I frequently doze off at inappropriate moments I have restless sleep I have difficulty falling asleep at night I have difficulty staying asleep I have difficulty getting back to sleep once awake I have morning tiredness I have fatigue during the day I frequently doze off at inappropriate moments Mood I feel a loss of interest I lack pleasure from things I used to enjoy I feel unhappy I am anxious, frightened or panicky I am depressed I feel a loss of interest I lack pleasure from things I used to enjoy I feel unhappy I am anxious, frightened or panicky I am depressed Other Non Motor Symptoms I feel light-headed/dizzy when standing from a lying position I fall due to fainting/blackouts I notice a change in my ability to smell/taste I notice a change in weight (not due to change in diet) I have excessive sweating I see/hear things that are not there I am unable to concentrate during activities I have slowness of speech I am forgetful I have difficulty remembering names, numbers, events I feel the urge to pass urine I get up at night to pass urine I have an altered interest in sex I have difficulty having sex The Parkinson s Well-Being Map TM contains several copies that you and/or your partner can use to: Monitor symptoms over time 0 0 0 0 0 0 0 0 DATE: (DD/MM/YY)... Parkinson s Well-Being Map TM DATE: (DD/MM/YY) I feel light-headed/dizzy when standing from a lying position I fall due to fainting/blackouts I notice a change in my ability to smell/taste I notice a change in weight (not due to change in diet) I have excessive sweating I see/hear things that are not there I lose my train of thought during conversations I am unable to concentrate during activities I have slowness of speech I am forgetful I have difficulty remembering names, numbers, events 0 0 0 0 0 0 0 0 I feel the urge to pass urine I get up at night to pass urine I have an altered interest in sex I have difficulty having sex I have difficulty swallowing I am dribbling/drooling (a lot of saliva) I have bouts of vomiting or feeling sick (nausea) I have constipation I have diarrhoea I have an upset stomach. I have early morning stiffness I have stiffness (Rigidity) I have shaking (Tremor) I have slowness of movement I have decreased/no ability to move I have dyskinesias I have impaired balance/falling I have a change in posture I have difficulty speaking. Summarise your health and well-being over the past month in preparation for your consultation.... I have difficulty swallowing I am dribbling/drooling (a lot of saliva) I have bouts of vomiting or feeling sick (nausea) I have constipation I have diarrhoea I have an upset stomach. For each aspect of your well-being (e.g. Mood,, etc. respresented with different colour codes):. Tick one or more boxes that best describes your experience of the symptoms over the past month,. Identify and circle the symptom that is most troublesome for you,. Rate the frequency of the most troublesome symptom by circling the most appropriate number on the 0 to scale where 0 Never Occasionally Sometimes Often Always. Connect up the numbers to create your Parkinson s Well-Being Map The aspect I want to focus on the most is My feet feel stuck to the floor/i have trouble starting to move My movements feel stiff (Rigidity) predominantly in the early morning after waking-up I have stiffness (Rigidity) throughout the day I have shaking (Tremor) I have slowness of movement (Bradykinesia) I have decreased ability to move at some times during the day I have involuntary movements (Dyskinesias) I lose my balance I fall over I lean towards or to the side I have trouble talking I have small handwriting (Micrographia). Moods I have early morning painful cramps (dystonia) affecting toes, fingers ankles, wrists causing you to wake up I have painful, stiff limbs during the day I have painful, stiff limbs at night I have shock-like shooting pain down my limbs I have pain with abnormal involuntary movements (dyskinesias) I have pain due to restlessness or fidgeting at night I have severe headaches The three most important questions to ask my care team are: I have early morning painful cramps (dystonia) affecting toes, fingers ankles, wrists causing me to wake up I have painful, stiff limbs during the day I have painful, stiff limbs at night I have shock-like shooting pain down my limbs I have pain with abnormal involuntary movements (Dyskinesia) I have severe headaches Parkinson s Well-Being Map TM Supporting communication of my Parkinson s I am taking the following medications Parkinson's medication Use the chart to identify and rate the Circle your most troublesome symptom frequency of your symptoms Levodopa + benserazide/madopar Levodopa + benserazide/madopar CR Levodopa + carbidopa/caramet CR Levodopa + carbidopa/duodopa Levodopa + carbidopa/sinemet Levodopa + carbidopa/sinemet CR Levodopa + carbidopa/half Sinemet Levodopa + carbidopa + entacapone/stalevo Bromocriptine/Parlodel Cabergoline/Cabaser Pergolide/Celance Pramipexole/Mirapexin Pramipexole/Mirapexin PR Ropinirole/Requip Ropinirole/Requip XL Rotigotine/Neupro Apomorphine/APO-go PEN Apomorphine/APO-go PFS Rasagiline/Azilect Selegiline/Eldepryl Selegiline/Zelapar Entacapone/Comtess Tolcapone/Tasmar Amantadine/Symmetrel Orphenadrine/Biorphen Orphenadrine/Disipal Procyclidine/Arpicolin Procyclidine/Kemadrin Trihexyphenidyl (benzhexol)/broflex Source:http://www.parkinsons.org.uk/advice/publications/ treatments_and_therapies/drug_treatments_of_parkinsons.aspx Fill the date on the top of the page. Over-the-counter medication (e.g. Aspirin)...... For each aspect of your well-being (e.g. Mood,, etc. represented with different colour codes), work alone or with your partner to identify the symptoms that you have experienced over the last month. For each symptom identified record its frequency in the box provided where: 0 = Never = Occasionally = Sometimes = Often = Always For each aspect of your well-being (e.g. Mood,, etc. represented with different colour codes), identify and circle the most troublesome symptom for you. CNS-OTH-0868-070 UK/NE08c DOP: February 0

How to complete the Parkinson s Well-Being Map TM (cont.) Rate the frequency of your most troublesome symptom Connect up your numbers 5 Other aspects of your Parkinson s Parkinson s Well-Being Map TM supporting communication of my Parkinson s For each aspect of your well-being (e.g. Mood,, etc. represented with different colour codes), rate the frequency of the most troublesome symptom by circling the most appropriate number on the 0- scale where: 0 = Never = Occasionally = Sometimes = Often = Always Connect up the numbers you have selected by drawing lines between them. This will generate a pattern which will provide an instant visual record of your current well-being. The aspect I want to focus on the most is Moods The three most important questions to ask my care team are: Parkinson s Medication below are suggested I am taking the following Parkinson s medications APO-go (Apomorphine) Mysolin (Primidone) Apomorphine (Apomorphine) Neupro (Rotigotine) Arpicolin (Procyclidine) Orphenadrine (Orphenadrine) Azilect (Rasagiline) Parlodel (Bromocriptine) Biorphen (Orphenadrine) Parlodel Capsules Broflex (Trihexyphenidyl) Pergolide (Pergolide) Bromocriptine (Bromocriptine) Pramipexole (Pramipexole) Cabaser (Cabergoline) Procyclidine (Procyclidine) Cabergoline (Cabergoline) Requip (Ropinirole) Co-beneldopa (Benserazide, Co-beneldopa, Levodopa) Requip XL (Ropinirole) Co-careldopa (Carbidopa, Co-careldopa, Levodopa) Ropinirole Comtess (Entacapone) Ropinirole Sustained Release Disipal (Orphenadrine) Selegiline (Selegiline) Duodopa (Carbidopa, Levodopa) Sinemet (Carbidopa, Co-careldopa, Levodopa) Eldepryl (Selegine) Sinemet CR (Carbidopa, Co-careldopa, Levodopa) Eldepryl Syrup Stalevo (Carbidopa, Entacapone, Levodopa) Half Sinement CR (Carbidopa, Co-careldopa, Levodpa) Symmetrel (Amantadine) Kemadrin (Procyclidine) Symmetrel Syrup (Amantadine) Madopar (Benserazide, Co-beneldopa, Levodopa) Tasmar (Tolcapone) Madopar CR (Benserazide, Co-beneldopa, Levodopa) Trihexyphenidyl (Trihexyphenidyl) Madopar Dispersible (Benserazide, Co-beneldopa, Levodopa) Zelapar (Selegiline) Mirapexin (Pramipexole) Highlight the Mirapexin symptoms Prolonged Release (Pramipexole) that are of most concern to you. List the three most important questions you wish to ask your care team at your next consultation. Medications you have taken over this period you may want to highlight any new medications you have started since the last consultation (including over-thecounter remedies such as aspirin etc). Once completed, the Map can be taken to your next consultation to share with your care team. CNS-OTH-0868-070 UK/NE08c DOP: February 0

Parkinson s Well-Being Map TM To complete your Parkinson s Well-Being Map TM refer to steps -5 detailed on the previous pages. DATE: (DD/MM/YY)... I have restless sleep I have difficulty falling asleep at night I have difficulty staying asleep I have difficulty getting back to sleep once awake I have morning tiredness I have fatigue during the day I frequently doze off at inappropriate moments Mood I feel a loss of interest I lack pleasure from things I used to enjoy I feel unhappy I am anxious, frightened or panicky I am depressed I feel light-headed/dizzy when standing from a lying position I fall due to fainting/blackouts I notice a change in my ability to smell/taste I notice a change in weight (not due to change in diet) I have excessive sweating I see/hear things that are not there To download additional maps go to www.parkinsons-voices.eu I lose my train of thought during conversations I am unable to concentrate during activities I have slowness of speech I am forgetful I have difficulty remembering names, numbers, events I feel the urge to pass urine I get up at night to pass urine I have an altered interest in sex I have difficulty having sex I have difficulty swallowing I am dribbling/drooling (a lot of saliva) I have bouts of vomiting or feeling sick (nausea) I have constipation I have diarrhoea I have an upset stomach. My feet feel stuck to the floor/i have trouble starting to move My movements feel stiff (Rigidity) predominantly in the early morning after waking-up I have stiffness (Rigidity) throughout the day I have shaking (Tremor) I have slowness of movement (Bradykinesia) I have decreased ability to move at some times during the day I have involuntary movements (Dyskinesias) I lose my balance I fall over I lean towards or to the side I have trouble talking I have small handwriting (Micrographia). I have early morning painful cramps (dystonia) affecting toes, fingers ankles, wrists causing me to wake up I have painful, stiff limbs during the day I have painful, stiff limbs at night I have shock-like shooting pain down my limbs I have pain with abnormal involuntary movements (Dyskinesia) I have severe headaches CNS-OTH-0868-070 UK/NE08c DOP: February 0

Parkinson s Well-Being Map TM Supporting communication of my Parkinson s The aspect I want to focus on the most is: I am taking the following medications: Moods The three most important questions to ask my care team are: Did I have time to ask all my questions? Parkinson s medication APO-go (Apomorphine) Apomorphine (Apomorphine) Arpicolin (Procyclidine) Azilect (Rasagiline) Biorphen (Orphenadrine) Broflex (Trihexyphenidyl) Bromocriptine (Bromocriptine) Cabaser (Cabergoline) Cabergoline (Cabergoline) Co-beneldopa (Benserazide, Co-beneldopa, Levodopa) Co-careldopa (Carbidopa, Co-careldopa, Levodopa) Comtess (Entacapone) Disipal (Orphenadrine) Duodopa (Carbidopa, Levodopa) Eldepryl (Selegine) Eldepryl Syrup Half Sinement CR (Carbidopa, Co-careldopa, Levodpa) Kemadrin (Procyclidine) Madopar (Benserazide, Co-beneldopa, Levodopa) Madopar CR (Benserazide, Co-beneldopa, Levodopa) Madopar Dispersible (Benserazide, Co-beneldopa, Levodopa) Mirapexin (Pramipexole) Mirapexin Prolonged Release (Pramipexole) Mysolin (Primidone) Neupro (Rotigotine) Orphenadrine (Orphenadrine) Parlodel (Bromocriptine) Parlodel Capsules Pergolide (Pergolide) Pramipexole (Pramipexole) Procyclidine (Procyclidine) Requip (Ropinirole) Requip XL (Ropinirole) Ropinirole Ropinirole Sustained Release Selegiline (Selegiline) Sinemet (Carbidopa, Co-careldopa, Levodopa) Sinemet CR (Carbidopa, Co-careldopa, Levodopa) Stalevo (Carbidopa, Entacapone, Levodopa) Symmetrel (Amantadine) Symmetrel Syrup (Amantadine) Tasmar (Tolcapone) Trihexyphenidyl (Trihexyphenidyl) Zelapar (Selegiline) Source: http://www.mims.co.uk/search/drugs/phrase/parkinsons Yes No Over-the-counter medication (e.g. aspirin)...... CNS-OTH-0868-070 CNS-OTH-0868-070 UK/NE08c DOP: UK/NE08c February 0DOP: February 0

The Cure Parkinson s Trust (CPT) The Cure Parkinson s Trust (CPT) was set up in 005 by four people living with the condition. It has one bold aim to cure Parkinson s. CPT funds innovative projects and inspirational scientists with the aim of building momentum towards a cure. We bring scientists together to improve communication and promote collaboration. We adopt a direct and no nonsense approach to making an impact in the research arena. As our policies are shaped by people living with Parkinson s, there is a refreshing passion and urgency in everything we do. The Cure Parkinson s Trust St Botolphs Aldgate High Street London ECN AB Tel: + (0) 07 99 7656 www.cureparkinsons.org.uk Registered charity number: 86 The Spanish Parkinson s Federation The Spanish Federation of Parkinson Disease (FEP) was established in November 996. It is currently composed of 5 associations spread throughout Spain which represent more than,500 associates. Our main objective is to improve the quality of life of patients and their families. To accomplish this, the FEP has projects related with research, training and information, free time, environment and nature, rehabilitation, or family support, among others. In the end, all projects developed improve the lives of those affected either by the training of caregivers, by promoting research or by providing rehabilitation for those affected such as physiotherapy, speech therapy, occupational therapy, psychological care, etc. which offers those affected the tools to reduce physical and psychological impact produced by the disease. The Spanish Federation of Parkinson s disease counts on the support and advice of a scientific committee composed of eight doctors with a broad professional background on Parkinson s disease. Federación Española de Párkinson Paseo Reina Cristina, 8 ºB 80 Madrid Tlf: + 9 57 www.fedesparkinson.org The European Parkinson s Disease Association (EPDA) The European Parkinson s Disease Association (EPDA) is the only European umbrella organisation for Parkinson s disease. A non-political, non-religious, and non-profit making organisation, it represents 5 member organisations and is the advocate for the rights and needs of over. million people with Parkinson s and their families. EPDA s vision is to enable a full life with Parkinson s whilst supporting the search for a cure and seeks to achieve this by raising awareness and reducing inequalities in the treatment and management of Parkinson s disease across Europe. The European Parkinson s Disease Association Northumberland Avenue Trafalgar Square London WCN 5BW United Kingdom Tel: + (0) 07 87 550 Email: info@epda.eu.com www.epda.eu.com CNS-OTH-0868-070 UK/NE08c DOP: February 0

Parkinson s Well-Being Map TM Supporting communication of my Parkinson s Contact Information UCB Pharma 08 Bath Road Slough Berkshire SL LE Web: www.ucbpharma.co.uk Medical Information: 075 5655 Developed in partnership with UCB. All rights reserved 0 UCB CNS-OTH-0868-070 UK/NE08c DOP: February 0 CNS-OTH-0868-070 UK/NE08c DOP: February 0